On August 11, 2022 VerImmune, Inc. ("VerImmune"), a biotechnology company developing new oncology therapeutic modalities that redirect the body’s pre-existing immunity toward cancer, reported that it has been accepted into the fully sponsored Assay Cascade characterization and testing program conducted by the Nanotechnology Characterization Laboratory (NCL) at the National Cancer Institute’s, part of the National Institutes of Health, Frederick National Laboratory for Cancer Research (Press release, VerImmune, AUG 11, 2022, View Source [SID1234618120]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nanomedicines accepted into the NCL Assay Cascade program undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy, and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies. All studies are funded by the NCI and conducted free of charge for Awardees.

"We are excited to be accepted into this highly competitive program sponsored by the National Cancer Institute" said John Troyer, COO of VerImmune Inc and Principal Investigator. "Acceptance into this program is an important step in validating our strategy since NCL accepts proposals with strong clinical potential. We look forward to this collaboration which will strengthen our existing manufacturing data for FDA submissions."